ClinicalTrials.gg
RecruitingNCT05382741VIVAUpdated May 17, 2023

Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial

A Phase 2 interventional study of Durvalumab Injection for intravenous use 500 mg vial solution for infusion and Regorafenib 30 mg capsules in Colorectal Cancer Stage IV and No Evidence of Disease State, sponsored by Ospedale Policlinico San Martino. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-17.

Sponsored by Ospedale Policlinico San Martino · Phase 2, Interventional, and Treatment

How we know · 5 judgments

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as recruiting.
  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing durvalumab in Colorectal Neoplasms — 4 open to participants now, 7 under way, none of them phase 3. durvalumab · Colorectal Neoplasms.

Planned enrollment
3rd of 21
182 · median 35
Started
2022
with 1 other
Phase 2
13 of 21
2 open now
Registered
19th of 21
by date

Among the 21 studies testing durvalumab in Colorectal Neoplasms, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2022, is one of 13 in phase 2, and was the 19th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

4 of the 21 studies testing durvalumab in Colorectal Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing durvalumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of Durvalumab plus Regorafenib versus observation for patients with stage IV colorectal cancer achieving the no evidence of disease state.

The NED state can be achieved in any line of treatment and it is defined as:

  1. R0 resection for surgery,
  2. the complete ablation defect covering the lesion on CT scan for radiofrequency,
  3. the erogation of ≥ 60 Gy for stereotactic radiotherapy,
  4. complete response to antineoplastic treatments on CT scan. In all these cases CEA and CA 19.9 must be within normal limits at the time of randomization.

Participants in this study will receive:

Experimental arm:

Regorafenib 90 mg d1-21 every 28 days plus Durvalumab 1500 mg every 28 days for 1 year

Control arm:

Observation (crossover to Experimental arm is allowed in case of relapse)

Tumor assessment will be performed every 12 weeks.

Read the detailed description

The safety run-in phase is planned for the first 4 patients randomized to the experimental arm using a starting dose of 60 mg/die of Regorafenib (and fixed 1500 mg of Durvalumab), to be escalated after 2 months to 90 mg/die if \< 2 patients report serious adverse events.

03

Conditions studied

  • Colorectal Cancer Stage IV
  • No Evidence of Disease State

Keywords

  • NED state
  • adjuvant
  • tyrosine kinase inhibitors
  • immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years; PS 0-1;
  2. Body weight >30 kg;
  3. confirmed diagnosis of colorectal adenocarcinoma;
  4. Patients must be in NED after completion of any treatments for stage IV CRC, including resections, RFA; RT with or without /adjuvant therapies or CR after chemotherapy;
  5. Patients must be randomized within 10 weeks since the achievement of the NED state. Those who have also received adjuvant therapy following the locoregional treatment are still eligible, provided they are randomized within 4 weeks since the last chemotherapy cycle;
  6. NED state ascertained by means of CT scan and/or PET scan and/or MRI scan;
  7. of at least 12 weeks;
  8. CEA within normal limits;
  9. No residual toxicity from previous chemotherapy;
  10. Adequate organ function;

Exclusion criteria

Exclusion criteria:

  1. MSI/dMMR patients;
  2. Any unresolved toxicity Grade ≥2 from previous anticancer therapy with the exception of alopecia and vitiligo;
  3. Active or prior documented or inflammatory disorders;
  4. Relevant concomitant comorbidities;
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    DURVALUMAB + REGORAFENIB

    Durvalumab 1500 mg (120-minute IV infusion) every 28 days, Regorafenib 90 mg/die orally once daily for 21 days in a 28-day cycle. Treatment will be administred up to 1 year.

    Drug: Durvalumab Injection for intravenous use 500 mg vial solution for infusion · Drug: Regorafenib 30 mg capsules

  • No intervention
    CONTROL ARM

    Observation (follow-up). Crossover to the experimental arm is allowed in case of relapse.

Interventions

06

What researchers measure

Primary outcomes

  1. Disease Free Survival

    Disease free survival, defined as the time from the date of randomization to the earliest documented disease relapse (local or distant), death due to any cause or two consecutive increases of CEA above upper limit (time gap no longer than 30 days).

    Time frame: approximately 48 months

Secondary outcomes

  1. 18 months - Disease Free Survival

    Disease free survival, defined as the time from the date of randomization to the earliest documented disease relapse (local or distant), death due to any cause or two consecutive increases of CEA above upper limit (time gap no longer than 30 days).

    Time frame: approximately 48 months

  2. Overall Survival

    Overall survival, defined as the time from the date of randomization to death due to any cause

    Time frame: approximately 48 months

  3. Incidence of adverse events

    An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Toxicity/adverse events are classified according to NCI CTCAE version 5.0.

    Time frame: approximately 48 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Mar 2024, 24 months after the start.

Of 499 non-industry phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 75. This study's planned 24 months is below that.

Counting every sponsor, half of 619 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2022
First posted
May 19, 2022
StartActual
Mar 2, 2022
Primary completionEst.
Mar 2, 2024
CompletionEst.
Mar 2, 2024
Last update
May 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05382741
Lead sponsor
Ospedale Policlinico San Martino
Collaborators
Associazione Italiana per la Ricerca sul Cancro, Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente, Bayer
Responsible party
Sponsor
First posted
May 19, 2022
Start date
Mar 2, 2022
Primary completion
Mar 2, 2024 (estimated)
Completion
Mar 2, 2024 (estimated)
Last update
May 17, 2023

Study contacts

Alberto Sobrero, MD
Contact
alberto.sobrero@hsanmartino.it
+39 010 555 4386
Alessandro Pastorino, MD
Contact
alessandro.pastorino@hsanmartino.it
+39 010 555 4386
Alberto Sobrero, MD
principal investigator · OSPEDALE SAN MARTINO IRCCS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Durvalumab · Regorafenib

Start the discussion